“EFFISAYIL™ 2 is the first and largest multinational randomized clinical trial to evaluate a treatment for the prevention of GPP flares,” said Bruce Strober, MD, PhD, Clinical Professor, Dermatology, ...

Erosive pustular dermatosis (EPD) is a chronic inflammatory skin disorder predominantly affecting the scalp of older individuals, often in areas of pre-existing actinic damage and androgenetic ...

Gram-negative folliculitis (GNF) is one of the most common mimics and complications of acne and acne rosacea. First described by Fulton in 1968, 1 GNF in acne patients is a relatively rare ...

New top-line data from a global Phase 3 clinical trial of patients with generalized pustular psoriasis (GPP) flares show rapid clearance of pustulation, erythema and scaling through four weeks after a ...

Please provide your email address to receive an email when new articles are posted on . The mean annualized flare rate per patient per year was 0.91, with a mean time of 5.9 months between flares.

AnaptysBio Inc ANAB released topline results from its global Phase 3 GEMINI-1 trial of imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP) flares. During a GPP flare, ...

Folliculitis is a common skin condition that occurs when hair follicles become inflamed due to infection, irritation, or blockage. The most frequent cause is a bacterial infection, though fungi and ...

Imsidolimab is an investigational humanized IgG4 antibody that inhibits the function of the interleukin-36 receptor. Findings from two phase 3 trials showed skin clearance was achieved and maintained ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

WASHINGTON, Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug ...